NCT05453487

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine in China: a Multicentre, Randomised, Controlled, Phase 4 Trial

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 360 (estimated)
• Sponsor: China National Biotec Group Company Limited · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Evaluation of immunogenicity and safety of inactivated COVID-19 vaccine (BBIBP-Cov) coadministered with rabies vaccine.

Detailed description

The participants aged ≥18 who had received two doses of inactivated COVID-19 vaccine were recruited and randomly assigned to one of three study groups: Co-Ad group, COVID-19 vaccine group and Rabies vaccine group. The participants in Co-Ad group and COVID-19 vaccine group received a booster dose of inactivated COVID-19 vaccine.The participants in Co-Ad group and Rabies vaccine group received three doses of rabies vaccine for pre-exposure immunization. The participants in Co-Ad group received the first dose of rabies vaccine (Day 0) and the inactivated COVID-19 vaccine simultaneously. Any local or systemic adverse events after vaccination will be recorded.

Conditions

• COVID-19
• Rabies

Interventions

Type	Name	Description
BIOLOGICAL	coadministration	the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and rabies vaccine
BIOLOGICAL	COVID-19 vaccine	received one dose of inactivated COVID-19 vaccine (BBIBP-CorV)
BIOLOGICAL	rabies vaccine	received three dose of rabies vaccine

Timeline

• Start date: 2022-07-21
• Primary completion: 2022-10-30
• Completion: 2023-06-30
• First posted: 2022-07-12
• Last updated: 2022-07-29

Locations

2 sites across 1 country: China